Transcatheter arterial chemoembolization with an interventional-CT system for recurrent hepatocellular carcinoma after living donor liver transplantation
Yamagami, T.; Yoshimatsu, R.; Ishikawa, M.; Kajiwara, K.; Aikata, H.; Tashiro, H.; Kakizawa, H.; Toyoda, N.; Ohdan, H.; Awai, K.
Hepato-Gastroenterology 61(133): 1387-1392
2014
ISSN/ISBN: 0172-6390 PMID: 25436316 Document Number: 16977
The aim of this retrospective study was to evaluate the feasibility and treatment effects of transcatheter arterial chemoembolization (TACE) for recurrent intrahepatic hepatocellular carcinoma (HCC) after liver transplantation. Between March 2007 and December 2012, we treated 8 patients (6 men and 2 women; mean age, 54 years) with recurrent HCC after living donor liver transplantation by TACE using an interventional-CT system. We retrospectively investigated treatment outcomes, complications, and the prognosis in these patients. Overall, 17 sessions of TACE were performed. A single TACE session was performed in 4 patients while multiple TACE sessions were performed in 4 patients. Anticancer drugs and embolic agents were selectively infused from the right hepatic artery (n=7), left hepatic artery (n=1), A3 (n=1), A5 (n=1), A6 (n=1), A7 (n=2), anterior branch (n=1), posterior branch (n=3), intercostal artery (n=1), and right inferior phrenic artery (n=5). There were no procedure-related complications. Response rate was 50%. The median overall survival from the initial TACE for recurrence of HCC was 12.9 months (95% confidence interval, 5 to 21). The 1-year survival rate was 42.9%. TACE with an interventional-CT system could play an important role in the treatment of recurrent HCC after liver transplantation.
Document emailed within 1 workday
